Synlogic is delivering the power of synthetic biology to medicine, combining the precision of engineering with rational drug development. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, we design Synthetic Biotic medicines to treat disease in new ways.

Synthetic biology brings engineering principles to science enabling the design of new biological systems, genetic circuits and molecular components that can be used to improve the world around us and create medicines that can have a meaningful impact for patients.

The Path to Possibilities

Starting in the 1960s, key advancements in the scientific understanding of how molecular networks regulate cellular function, and how gene expression is regulated within cells, laid the foundation for synthetic biology. Further catalyzed by advances in molecular biology tools and DNA sequencing, a new era in biology was born: an era in which genetic toggles, feedback circuits, and other tools enabled the programming of bacterial cells analogous to the programming of a computer.

With the completion of the landmark Human Genome Project in 2003, scientists were able to understand the genetic basis behind disease in new ways. The 2000s were also the first time bacteria were successfully reprogrammed to carry out specific functions, including attacking cancer cells and producing biofuel. In the last decade, synthetic biology has taken flight.

Synlogic was founded in 2014 as the first synthetic biology company entirely focused on therapeutics – a new therapeutic modality known as Synthetic Biotic medicines.

Driving Progress for Patients

Biology defines the path we are on – providing important indicators that reveal the potential of Synthetic Biotic medicine across diseases. From metabolic diseases where we design bacteria to play a precise therapeutic role in the gastro-intestinal (GI) tract to immunomodulation where our novel science and approach is built on advances in the understanding of the interaction between bacteria and the immune system, we use synthetic biology as a technology to design medicines that will change lives.

The Synlogic Approach: Designing Synthetic Biotic Medicines

Synlogic is pioneering the development and use of Synthetic Biotics in medicine. Our Synthetic Biotic platform combines deep synthetic biology expertise with an innovative manufacturing approach and translational ingenuity to build a pipeline of live bacterial, first-in-class Synthetic Biotic medicines. By bringing together molecular biology, microbial engineering and disease physiology with our proprietary library of innovative tools and modular components, such as state-of-the art metabolic gene circuitry and regulatory genetic switches that activate the medicine in its intended environment, we are able to produce bacterial microbes designed to perform specific therapeutic functions.

Synlogic is delivering the power of synthetic biology to medicine, combining the precision of engineering with rational drug development. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, we design Synthetic Biotic medicines to treat disease in new ways.

Synthetic biology brings engineering principles to science enabling the design of new biological systems, genetic circuits and molecular components that can be used to improve the world around us and create medicines that can have a meaningful impact for patients.

The Path to Possibilities

Starting in the 1960s, key advancements in the scientific understanding of how molecular networks regulate cellular function, and how gene expression is regulated within cells, laid the foundation for synthetic biology. Further catalyzed by advances in molecular biology tools and DNA sequencing, a new era in biology was born: an era in which genetic toggles, feedback circuits, and other tools enabled the programming of bacterial cells analogous to the programming of a computer.

With the completion of the landmark Human Genome Project in 2003, scientists were able to understand the genetic basis behind disease in new ways. The 2000s were also the first time bacteria were successfully reprogrammed to carry out specific functions, including attacking cancer cells and producing biofuel. In the last decade, synthetic biology has taken flight.

Synlogic was founded in 2014 as the first synthetic biology company entirely focused on therapeutics – a new therapeutic modality known as Synthetic Biotic medicines.

Driving Progress for Patients

Biology defines the path we are on – providing important indicators that reveal the potential of Synthetic Biotic medicine across diseases. From metabolic diseases where we design bacteria to play a precise therapeutic role in the gastro-intestinal (GI) tract to immunomodulation where our novel science and approach is built on advances in the understanding of the interaction between bacteria and the immune system, we use synthetic biology as a technology to design medicines that will change lives.

The Synlogic Approach: Designing SYNTHETIC BIOTIC Medicines

Synlogic is pioneering the development and use of Synthetic Biotics in medicine. Our Synthetic Biotic platform combines deep synthetic biology expertise with an innovative manufacturing approach and translational ingenuity to build a pipeline of live bacterial, first-in-class Synthetic Biotic medicines. By bringing together molecular biology, microbial engineering and disease physiology with our proprietary library of innovative tools and modular components, such as state-of-the art metabolic gene circuitry and regulatory genetic switches that activate the medicine in its intended environment, we are able to produce bacterial microbes designed to perform specific therapeutic functions.

Metabolic Disease

Medicines for metabolic disease are our core area of focus, driven by validated biology demonstrating the effectiveness of GI based interventions. There are a large number of inherited and acquired diseases with significant unmet need:

Phenylketonuria or PKU

Patients living with PKU are not able to break down the phenylalanine amino acid (Phe) that is found in many foods, including vegetables, breads, and cereals. The buildup of Phe then leads to severe neurological disorders and developmental delays. SYNB1618 is an oral investigational Synthetic Biotic medicine designed to break down Phe in the GI tract, potentially reducing plasma Phe levels, allowing patients to consume
Enteric Hyperoxaluria

Enteric Hyperoxaluria

Enteric Hyperoxaluria (HOX) is a complication of bowel conditions, including inflammatory bowel diseases, bariatric/weight-loss surgery, short bowel syndrome, and others. The disorder, which is caused by the overabsorption of oxalate in the GI tract, results in dangerously high urinary oxalate levels that damage the kidneys. Recurrent kidney stones, chronic kidney disease, and nephrocalcinosis (hardening of the kidney due to toxic calcium oxalate crystal deposits) may result. There are currently no approved treatments. SYNB8802 is an oral investigational Synthetic Biotic medicine designed to break down oxalate in the GI tract, lower levels of oxalate in the urine, and reduce the risk for related kidney damage.

Immunomodulation

The immune system and bacteria are linked in intricate ways. Trillions of bacteria live on and around each one of us, interacting with our immune system. Bacteria have evolved and created mechanisms to control our immune response. We are harnessing the interactions between bacteria and the immune system, and adding the tools of synthetic biology, to rationally design Synthetic Biotic medicines that modulate the immune response to fight cancer and auto-immune diseases.

Solid Tumors & Lymphomas

Cancer cells have long been masters at evading our immune system — allowing dangerous tumor cells to proliferate and metastasize. Immunotherapies, such as immune checkpoint inhibitors, which are used to upregulate the immune response, are increasingly employed to harness the patient’s own immune system against the tumor. However, only a minority of patients respond to these therapies.

Investigational Synthetic Biotic medicine SYNB1891 is designed to activate inflammatory cytokines via multiple mechanisms of action including the STING pathway. Because the STING pathway is not activated until SYNB1891 is taken up by immune system cells inside the tumor micro-environment, SYNB1891 may more effectively upregulate STING compared to small molecule approaches. SYNB1891 is given via a direct injection into the tumor and is being studied both alone and in combination with antibodies that stimulate the immune response.

Inflammatory Bowel Disease

Inflammatory bowel diseases such as Crohn’s Disease or Ulcerative Colitis result in chronic inflammation in the intestinal tract driven by an over activation of the immune system. These diseases can be severe, resulting in debilitating abdominal pain and GI distress, and ultimately surgical interventions. Current therapies based on systemic immunosuppression work in some patients, but fail to induce and maintain long-term remission in the majority of patients. Given the role bacteria play in interacting with the immune system, we are exploring a variety of approaches for Synthetic Biotic medicines that may suppress the overactive immune response, improve the leakiness of the GI tract lining, and reduce the signs and symptoms of disease.